Entering text into the input field will update the search result below

Axonics wins FDA approval for recharge-free neuromodulation device

Mar. 07, 2022 4:21 PM ETAxonics, Inc. (AXNX)MDTBy: Dulan Lokuwithana, SA News Editor

Headquarters of US Food and Drug Administration (FDA)

Grandbrothers/iStock Editorial via Getty Images

  • MedTech company Axonics (NASDAQ:AXNX) announced on Monday that the U.S. Food and Drug Administration (FDA) approved Axonics F15, its new recharge-free sacral neuromodulation (SNM) implantable neurostimulator (INS).
  • Axonics F15 is designed to last for

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.